Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


2 06, 2013

Elotuzumab study results “promisingly murky”

Tags: , , , , |12 Comments

For me, one of the most frustrating part of reading abstracts and following oral presentation myeloma results at meetings like ASCO and ASH is that you are rarely comparing apples to apples.  Are study subjects "heavily pretreated," "refractory," or both.  And what about "relapsed?"  Sometimes some of these terms are used interchangeably.  Sometimes not.  Let

16 04, 2013

What took so long? Pomalidomide time-line raises questions–I have answers (Part Two)

Tags: , , , , , , , , , , , |7 Comments

Before I get started, did you happen to see the MMRF's Kathy Giusti interviewed in the trendy tech magazine, Fast Company?  Interesting approach.  Simply click-on the headline link below to access the interview: Using Data To Treat Cancer And Drive Innovation How a pair of savvy renegades are forcing collaboration in cancer R&D--and saving lives.

11 04, 2013

Stranger than fiction? Cialis an anti-myeloma drug?

Tags: , , , , , , |18 Comments

I ended yesterday's post with a flip blip about how Cialis features a precautionary warning specifically naming mutliple myeloma.  Ironic, since our good friend, Holt, followed-up with an even stranger Cialis-related email.  Turns-out that Cialis (tadalafil) is being tested in ongoing human studies as an anti-multiple meyloma drug!  You can't make this stuff up! According

15 02, 2013

New study pinpoints Velcade as drug of choice for high risk myeloma patients

Tags: , , , , , , , , |11 Comments

Our good friend and nutritional columnist, Danny Parker, is excited about a new study released last week in the Journal of the American Society of Hematology:  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Danny is considered a high risk patient, so I understand why this comprehensive study

4 09, 2012

The million dollar question: How long do I need to stay on maintenance therapy?

Tags: , , , , |16 Comments

"My myeloma is stable.  How long do I need to stay on maintenance therapy?" This is the million dollar question for nearly all multiple myeloma patients at some time during their myeloma journey. More and more articles like the one below nudge us toward the decision to stay on maintenance indefinitely.  Give it a quick

9 04, 2012

The crazy world of “myeloma research speak”

Tags: , , , , , , , , , , , , , |0 Comments

Most of you probably know that I have been working on several new books about multiple myeloma.  My third book, New Myeloma Therapies from a Patient's Perspective, will be published and available by the end of this month.  Researching this book reminded me about how difficult it can be to understand "myeloma research speak."  It

13 08, 2011

Revlimid Dosing Being Re-Evaluated…

Tags: , , |0 Comments

This article concerns and fascinates me--all at the same time.  I discovered it earlier this week on a site called "Back to EurekAlert! Since it is technically a press release, I am going to reproduce it here in it's entirety.  While it is great that researchers have discovered lenalidomide (Revlimid) interacts with a protein in

9 06, 2011

ASCO Odds/Ends And Clinical Study Links

Tags: , , , , , , , , , , |0 Comments

A few more quick notes from ASCO before the first of a long running series about ways to improve peripheral neuropathy (PN) starts later today: Secondary Cancer Risk From Using Revlimid: Based on the results of this retrospective analysis, Dr. Palumbo concluded that Revlimid ,when used with melphalan, increases the rate of secondary cancers.  The

12 04, 2011

FDA Revlimid/Thalomid Investigation Update

Tags: , , , , , |1 Comment

The Myeloma Beacon just broke the story about how the FDA is investigating Revlimid and Thalomid, based on research data showing a possible secondary cancer risk following long term, post transplant use. Here is an independent look at the pending investigation by Internal Medical News.  I have highlighted key points I feel are important: FDA Keeping an

19 12, 2010

American Society of Clinical Oncology Recognizes Revlimid As One Of The Year’s "Most Notable Advances."

Tags: , , , , |0 Comments

The American Society of Clinical Oncology (ASCO) issues an annual report yearly.  Revlimid is prominently mentioned in this years report, published in the Journal of Clinical Oncology, in the "Notable Advances" category.  Here is what the report had to say about Revlimid (lenalidomide):Lenalidomide maintenance therapy slows myeloma progression.Multiple myeloma, a cancer of plasma cells in

11 10, 2010

New Italian Study Shows Two Different Approaches To Treating Newly Diagnosed Multiple Myeloma Patients Both Work–But Stem Cell Transplants Still Achieve Highest Percentage Of Complete Response (CR)

Tags: , , , , |0 Comments

e-CancerMedicalScience/Oncology ran a story about the ESMO 35 Italian study Sunday:ESMO 35: High response rates seen in Phase-III trial of chemotherapy, new drug and stem cells in myelomaPublished: 10/10/2010 15:01:57 The first study of its kind comparing two different approaches to treating newly diagnosed multiple myeloma has found that both treatments achieved a positive response,

9 08, 2010

New Clinical Oncology Newsletter Article Analyzing ASCO Study Findings About Using Revlimid Maintenance Therapy

Tags: , , , , , , , |0 Comments

Here is an article I found in this week's Clinical Oncology newsletter.  No new news, but some insight into how stats effect progression free surivival (PFS).In Multiple Myeloma, Maintenance Therapy After Transplant Improves PFS Ted BosworthChicago—Maintenance therapy with lenalidomide (Revlimid, Celgene) greatly improves progression-free survival (PFS) in patients with multiple myeloma (MM) after autologous stem

30 07, 2010

Link To Myeloma Beacon Story About Improving Survival Rates For Multiple Myeloma Patients

Tags: , , , , |3 Comments

Here is the first part of a story which ran Wednesday in The Myeloma Beacon:Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma PatientsBy Michelle Spektor - Published July 28, 2010A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission

19 07, 2010

Post Stem Cell Transplant Maintenance Therapy Delays Multiple Myeloma Relapse In A Majority Of Patients

Tags: , , , , , |3 Comments

One more stem cell transplant (SCT) follow-up point and story.  Medscape Medical News posted an article, Lenalinomide Maintenance Halves Multiple Myeloma Relapse, written by Zosia Chustecka just before the ASCO meetings this spring:May 26 2010 — Patients with multiple myeloma who were treated with high-dose chemotherapy and autologous stem cell transplantation and then went on

13 07, 2010

More About When To Get A Stem Cell Transplant (SCT) & Success Of RVD Drug Combo

Tags: , , , , , , , , , |0 Comments

Here is the body of the article about multiple myeloma related research studies I started to post yesterday,  Is It Time to Abandon Up-Front Transplantation in Multiple Myeloma? Elsevier Global Medical News, written by P. Wendling on the medical professionals only site, Oncology STAT: He (Dr. Jean-Luc Harousseau) cited data from several trials, including the pivotal phase

5 07, 2010

How/Why Does Revlimid Work?

Tags: , , , , , |1 Comment

I have now been using Revlimid (lenalidomide) for 35 consecutive months and it is still working! But how does it work? Lenalidomide is an immune-modulating therapy that acts to improve the immune system. Administered orally, lenalidomide also helps block the blood supply to cancer cells so that tumors cannot grow. Lenalidomide is molecular variation, or analogue,

21 06, 2010

A Look At Which Multiple Myeloma ASCO News Seemed Most Important To General Cancer Related Sites

Tags: , , , |0 Comments

Medpage Today just ran an article about anti-cancer related advances from ASCO.  I always find it interesting to take a look at what more general cancer related sites consider noteworthy about the world of multiple myeloma.  This extensive article only featured one myeloma related study from ASCO: CHICAGO -- A chemical cousin to the infamous